Go Deep
Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -25,468 | -0.1 | -1.26 | -9.06 | 13.53 |
| Oct 2026 | -25,398 | -0.1 | -1.16 | -9.06 | 12.42 |
| Oct 2026 | -28,220 | -0.1 | -1.19 | -9.06 | 12.79 |
| Oct 2026 | -28,255 | -0.1 | -1.24 | -9.06 | 13.33 |
| Oct 2026 | -28,219 | -0.1 | -1.19 | -9.06 | 12.74 |
| Oct 2026 | -28,206 | -0.1 | -1.17 | -9.06 | 12.51 |
Vivos Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 5,153,000.0 | 5,141,000.0 | 3,824,000.0 | 6,783,000.0 |
| Net Profit | -5,481,000.0 | -7,682,000.0 | -6,954,000.0 | -5,400,000.0 |
| EPS | -0.3 | -0.5 | — | -0.5 |
Vivos Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 17,443,000.0 | 15,031,000.0 | 13,801,000.0 | 16,024,000.0 | — |
| Net Profit | -21,230,000.0 | -11,136,000.0 | -13,583,000.0 | -23,845,000.0 | — |
| EPS | -2.1 | -2.2 | -11.1 | -25.9 | — |
Vivos Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 25,152,000.0 | 15,284,000.0 | 10,730,000.0 | 13,720,000.0 | — |
| Total Liabilities | 26,702,000.0 | 7,330,000.0 | 10,319,000.0 | 8,919,000.0 | — |
| Total Equity | -1,490,000.0 | 7,954,000.0 | 411,000.0 | 4,801,000.0 | — |
Owes vs Owns
Vivos Therapeutics, Inc. owed $1.17 for every $1 it owned in Jun 2026, up from $0.65 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.17× | 1.06× | 0.48× | 0.96× | 0.65× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Vivos Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 8.1%Receivables 6.3%Fixed assets (tangible) 31.5%Intangible assets 50.2%Other assets 4.0%
How it's funded — Dec 2025
Short-term debt 31.3%Long-term debt 1.8%Payables 6.3%Other liabilities 60.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2.0 | 6.3 | 1.6 | 3.5 |
| Receivables | 1.6 | 0.4 | 0.2 | 0.5 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 7.9 | 4.3 | 4.7 | 4.8 |
| Intangible assets | 12.6 | 3.3 | 3.3 | 3.1 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.0 | 1.0 | 0.9 | 1.8 |
| Liabilities & equity | ||||
| Short-term debt | 8.4 | 0.5 | 0.5 | 0.4 |
| Long-term debt | 0.5 | 1.0 | 1.5 | 2.0 |
| Payables | 1.7 | 1.1 | 2.1 | 1.4 |
| Other liabilities | 16.2 | 4.7 | 6.2 | 5.1 |
| Shareholders' equity | -1.6 | 8.0 | 0.4 | 4.8 |
| Net tangible assets | -14.1 | 4.7 | -2.9 | 1.7 |
Vivos Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -15,263,000.0 | -12,691,000.0 | -11,946,000.0 | -19,587,000.0 | — |
| Investing Activities | -7,526,000.0 | -568,000.0 | -853,000.0 | -924,000.0 | — |
| Financing Activities | 18,558,000.0 | 17,876,000.0 | 10,923,000.0 | 0.0 | — |